Alison J. Moskowitz

Hematology | Oncology
530 E 74th St
New York, NY 10021

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 192 publications

Classic Hodgkin Lymphoma: A Review.

Classic Hodgkin Lymphoma: A Review.

Journal: JAMA
Published: August 03, 2026

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications.

Journal: Haematologica
Published: May 18, 2026

Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.

Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.

Journal: Cancers
Published: May 12, 2026

The use of supplemental oxygen during cardiopulmonary resuscitation - a systematic review of the literature.

The use of supplemental oxygen during cardiopulmonary resuscitation - a systematic review of the literature.

Journal: Resuscitation plus
Published: March 13, 2026

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns.

Journal: Haematologica
Published: March 06, 2026

Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? - the CON.

Relapsed Hodgkin disease: Should all patients receive an autologous stem cell transplant? - the CON.

Journal: Haematologica
Published: February 26, 2026

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Journal: Blood advances
Published: February 24, 2026

Early-Stage Hodgkin Lymphoma: Time for Novel Agents?

Early-Stage Hodgkin Lymphoma: Time for Novel Agents?

Journal: Hematology/oncology clinics of North America
Published: February 18, 2026

New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma.

New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma.

Journal: Hematology/oncology clinics of North America
Published: February 10, 2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

Journal: Blood cancer journal
Published: February 02, 2026

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Journal: Blood advances
Published: January 05, 2026

American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma.

American Society of Transplantation and Cellular Therapy Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma.

Journal: Transplantation and cellular therapy
Published: December 09, 2025
Showing 1-12 of 192

Last Updated: 09/26/2026